Clinical Validity/Utility, Change in Practice Patterns, and Economic Implications of Risk Stratifiers to Predict Outcomes for Early-Stage Breast Cancer: A Systematic Review
Journal of the National Cancer Institute, 07/06/2012
Hornberger J et al. – The available evidence on the ability of stratifiers to predict risks of recurrence and response to chemotherapy in early–stage breast cancer (ESBC) is growing. Level–of–Evidence determinations using the newer framework provide a solid scientific foundation for clinical recommendations.